Rezolute (RZLT) Convertible Debt (2011 - 2018)

Rezolute (RZLT) reported Convertible Debt of $5.0 million for Q4 2018, up 3.43% sequentially from $4.8 million in Q3 2018.

Rezolute (RZLT) Convertible Debt (2011 - 2018) Analysis & Trends

Rezolute (RZLT) has 3 years of Convertible Debt data on file, last reported at $5.0 million in Q4 2018.

For the quarter ending Q4 2018, Convertible Debt changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2018 stood at $5.0 million (changed N/A YoY), and the FY2011 full-year result was $54958.0, changed N/A from the prior year.
Convertible Debt advanced to $5.0 million in Q4 2018, from $4.8 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $5.0 million in Q4 2018 to a low of $4.8 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Rezolute	31,153.77	31,153.77	-

Download Data